Its role in HA-driven motility and angiogenesis has been implicated in tumor progression, and recent preclinical studies have shown that peptide or siRNA-based RHAMM inhibition can attenuate HCC growth and vascular remodeling in a murine HepG2 xenograft model [112]. The gene discussed is HMMR; the disease is hepatocellular carcinoma.